Brief: Actinium Pharmaceuticals Inc Announces Clinical Trial Site Expansion In Its MultiCenter Phase 1/2 Actimab-A Venetoclax Combination Trial
06/10/2020 12:03
Oct 6 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS, INC. ANNOUNCES CLINICAL TRIAL
SITE
EXPANSION IN ITS MULTI-CENTER PHASE 1/2 ACTIMAB-A VENETOCLAX
COMBINATION TRIAL
* ACTINIUM PHARMACEUTICALS - EXPECTS CONTINUED SITE
ADDITIONS AND
ANTICIPATES PROOF OF CONCEPT RESULTS FROM PHASE 1 PORTION OF
TRIAL IN 2021
Source text for Eikon: ID:nPn7r43h7a
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities